X0306 4 2019-12-09 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001772518 Ridloff Elena C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 0 1 0 0 EVP and CFO Common Stock 2019-12-09 4 M 0 36000 15.81 A 36000 D Common Stock 2019-12-09 4 S 0 11020 50.595 D 24980 D Common Stock 2019-12-09 4 S 0 5502 49.808 D 19478 D Common Stock 2019-12-09 4 S 0 19478 49.094 D 0 D Stock Option (Right to Buy) 15.81 2019-12-09 4 M 0 36000 0.00 D 2028-04-29 Common Stock 36000 64000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.75 to $49.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the 100,000 shares originally subject to the stock option vested and became exercisable on April 30, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Austin D. Kim, Attorney-in-Fact 2019-12-11